

COMPLETION OF THE ACQUISITION OF SHARES IN SMG INTERNATIONAL (VIETNAM) PTE. LTD.

The Board of Directors (the "**Board**") of Singapore Medical Group Limited (the "**Company**") refers to the announcements dated 19 August 2021 and 1 September 2021 (the "**Earlier Announcements**") in relation to the proposed acquisition of 850,000 issued and fully paid ordinary shares representing the remaining 50% of the issued and paid up share capital in SMG International (Vietnam) Pte. Ltd. (the "**Proposed Acquisition**").

All capitalised terms used and not defined herein shall have the same meanings given to them in the Earlier Announcements.

The Board is pleased to announce that the Company has, on 13 September 2021 (the "**Completion Date**") completed the Proposed Acquisition and SMG International (Vietnam) Pte. Ltd. has become a wholly-owned subsidiary of the Company.

The consideration of the Proposed Acquisition was satisfied by cash of S\$1,949,176 paid to the Vendors and the allotment and issuance of 3,398,203 Consideration Shares at S\$0.321 per Consideration Share to certain Vendors. The Consideration Shares rank *pari passu* in all respects with the existing ordinary shares of the Company as at the Completion Date. Following the allotment and issuance of the Consideration Shares, the total number of issued and paid-up shares in the share capital of the Company (excluding treasury shares) increased from 482,983,906 shares to 486,382,109 shares. The Consideration Shares are expected to be listed and quoted on the Catalist Board of the SGX-ST on or around 15 September 2021.

By Order of the Board

Beng Teck Liang
Executive Director and Chief Executive Officer
13 September 2021

*This announcement has been prepared by Singapore Medical Group Limited (the "**Company**") and its contents have been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "**Sponsor**") for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist.*

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881.